

# IHI Call Days | Call 9

- EU-Wide Innovative PCM Platform  
Neoadjuvant Therapy

Contact person name: Nancy Frédérickx & Marc Van Den Bulcke

Organisation: Sciensano - Cancer Center

E-mail: [Nancy.Frederickx@sciensano.be](mailto:Nancy.Frederickx@sciensano.be) & [Marc.VanDenBulcke@sciensano.be](mailto:Marc.VanDenBulcke@sciensano.be)

Link to the IHI brokerage platform:

- [EU-wide innovative PCM Platform](#)
- [Nancy Frédérickx](#)

# Challenges and Objectives

**Topic 2:** Boosting innovation through better integration of fragmented health R&I efforts (SO2-SRIA)

Personalized neoadjuvant treatments have the potential to reduce the cancer burden across various type. Yet, its widespread adoption faces significant challenges:

- Complexity of clinical trial organization
- Integration of innovative technologies
- Regulatory hurdles
- Limited sustainable access

**AIM:**

To establish an EU-Wide Platform for Neoadjuvant therapy that reshapes clinical trial organization and promote unity and efficiency


# Key Elements of the Proposal I

- Create a unified platform for neoadjuvant therapy
  - Support standardized trial setups
  - Integration of cutting-edge technologies
  - Standardise sampling processing method
  - Promote access to skilled personnel



UK Cancer Immunotherapy Response Research Platform

Our approach is built with patients in mind



Benefits of our approach



Targeted access to neoadjuvant patients



Wide network



Long list of partners allows us to cast a wide net



Homogenous trial set-up



Ability to collect large range of samples



In-depth multi-omics analysis on high quality material



# Key Elements of the Proposal II

- Pave the way to establish a neoadjuvant learning system
  - Accelerate therapy development & promote cancer care
- Foster synergy with EU Initiatives
  - EUnetCCC and upcoming Joint action PCM
- Support and facilitate regulatory alignment

# IHI Ideal Instrument

Public-private collaboration within the healthcare system is essential to:

- Share infrastructure,
- Develop robust implementation frameworks,
- Address regulatory challenges

Specific contributions in

- Access to new therapies and clinical trial expertise
- Advanced multi-omics technologies and translational research
- Centralise digital platforms and data integration (AI/ML)
- Insights and guidance for local deployment

# Platform Impacts and Outcomes

## Impacts

- Streamline Clinical Trials & Speed Development
- Identify Surrogate Outcome Markers to Support Regulatory Framework
- Integrate Advanced Technologies (e.g., Omics)

## Outcomes

- Pave the Way for a Neoadjuvant Learning System
- Standardized Sample Collection and Methods
- Collect Robust Evidence for Regulatory Transformation
- Enhance Sustainable Access & Patient Outcome

# Expertise and Resources

- We have:
  - Public Health and Clinical Expertise
  - Public-private project management
    - Including communication, dissemination and exploitation
  - Multi-Omics, Molecular Biology, and Data Integration
  - EU oncology research & care Network
  - Strong connection with EU oncology initiative (coordinator of JA PCM)
- We are looking for expertise in:
  - Pharmaceutical Development
  - Advanced Multi-Omics Analysis
  - Data Management and Analytics
  - AI-Driven Cancer Diagnostics
  - Health Informatics
  - Regulatory bodies
  - Patient Advocacy group



This platform will accelerate the field of neoadjuvant therapies, transforming cancer care and improving patient outcomes across Europe



**KU LEUVEN**

